COFC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|---|---|---|
| Patent No. | : | 7,241,747 |
| Applicant | : | Hector F. DeLuca et al |
| Filed | : | April 9, 2004 |
| Title | : | 2-Propylidene-19-Nor-Vitamin D Compounds |
| TC/A.U. | : | 1616 |
| Examiner | : | Qazi, Sabiha Naim |
| Docket No. | : | 1256-00946 |

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being submitted deposited with the United States Postal Service on this 26th day of August, 2008, addressed to Certificate of Correction Branch, PO Box 1450, Alexandria, VA 22313-1450.

Marie Mikolainis — 8-26-08 Date

SECOND REQUEST FOR CERTIFICATE OF CORRECTION

Certificate of Correction Branch
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450



Sir:

Upon receipt of the original patent document, the face and claims were proofread and the following printing errors were noted. A Certificate of Correction, according to the enclosed form, is therefore requested, as follows:

**In the Claims**:

CLAIM 20
Col. 47, Line 59
(Claim 20, Line 1)
Amend. 02/06/2007

Delete "The" and substitute therefor --- A ---

CLAIM 21
Col. 47, Line 67
(Claim 21, Line 3)
Amend. 02/06/2007

After "gram" insert --- of ---



CLAIM 28
Col. 48, Line 23
(Claim 28, Line 3)
Amend. 02/06/2007

Delete "g" and substitute therefor --- μg ---

| | |
|---|---|
| CLAIM 79<br>Col. 55, Line 39<br>(Claim 85, Line 24)<br>Amend. 02/06/2007 | Delete "–$CR_1R_2$)–" and substitute therefor --- –($CR_1R_2$)– --- |
| CLAIM 92<br>Col. 56, Line 44<br>(Claim 98, Line 9)<br>Amend. 02/06/2007 | Delete "–C≡–CY" and substitute therefor --- –C≡CY --- |
| CLAIM 92<br>Col. 57, Line 7<br>(Claim 98, Line 24)<br>Amend. 02/06/2007 | Delete "–$CR_1R_2$)–" and substitute therefor --- –($CR_1R_2$)– --- |

**Remarks**

A first Request for a Certificate of Correction was made August 29, 2007, but Applicant has not received the Certificate to date. Therefore, this Second Request is being filed.

The errors noted in the Inventors section and claims are printing errors made by the Patent Office and correction is desired for clarification purposes when reading the patent.

Issuance and entry of the enclosed Certificate of Correction is respectfully requested.

Respectfully submitted,

ANDRUS, SCEALES, STARKE & SAWALL, LLP

Thomas M. Wozny
Reg. No. 28,922



Andrus, Sceales, Starke & Sawall, LLP
100 East Wisconsin Avenue, Suite 1100
Milwaukee, Wisconsin 53202
Telephone: (414) 271-7590
Facsimile: (414) 271-5770

PTO/SB/44 (02-01)
Approved for use through 01/31/2004. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

# UNITED STATES PATENT AND TRADEMARK OFFICE
## CERTIFICATE OF CORRECTION



PATENT NO: 7,241,747

APPLICATION NO.: 10/821,479

ISSUE DATE: July 10, 2007

INVENTOR(S): Hector F. DeLuca et al

It is certified that error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

**In the Claims:**

CLAIM 20
Col. 47, Line 59
(Claim 20, Line 1)
Amend. 02/06/2007

Delete "The" and substitute therefore:
--- A ---

CLAIM 21
Col. 47, Line 67
(Claim 21, Line 3)
Amend. 02/06/2007

After "gram" insert
--- of ---

CLAIM 28
Col. 48, Line 23
(Claim 28, Line 3)
Amend. 02/06/2007

Delete "g" and substitute therefore:
--- μg ---

CLAIM 79
Col. 55, Line 39
(Claim 85, Line 24)
Amend. 02/06/2007

Delete "–$CR_1R_2$)–" and substitute therefore:
--- –($CR_1R_2$)– ---

CLAIM 92
Col. 56, Line 44
(Claim 98, Line 9)
Amend. 02/06/2007

Delete "–C≡–CY" and substitute therefore:
--- –C≡CY ---



CLAIM 92
Col. 57, Line 7
(Claim 98, Line 24)
Amend. 02/06/2007

Delete "–$CR_1R_2$)–" and substitute therefore:
--- –($CR_1R_2$)– ---

MAILING ADDRESS OF SENDER:

Andrus, Sceales, Starke & Sawall, LLP
100 East Wisconsin Avenue, Suite 1100
Milwaukee, WI 53202

16. (Original) 2-(3'-hydroxypropylidene)-19-nor-(20S)-1α,25-$(OH)_2D_3$ (Z-isomer) having the formula:




17. (Original) A pharmaceutical composition containing an effective amount of at least one compound as claimed in claim 1 together with a pharmaceutically acceptable excipient.

18. (Original) The pharmaceutical composition of claim 17 wherein said effective amount comprises from about 0.01μg to about 100μg per gram of composition.

19. (Original) The pharmaceutical composition of claim 17 wherein said effective amount comprises from about 0.1μg to about 50μg per gram of composition.



20. (Previously Presented) A pharmaceutical composition containing 2-[(3'-methoxymethoxy)propylidene]-19-nor-1α,25-$(OH)_2D_3$ in an amount from about 0.01μg to about 100μg per gram of composition.

21. (Previously Presented) The pharmaceutical composition of claim 20 containing 2-[(3'-methoxymethoxy)propylidene]-19-nor-1α,25-$(OH)_2D_3$ in an amount from about 0.1μg to about 50μg per gram of composition.

22. (Original) The pharmaceutical composition of claim 17 containing 2-(3'-hydroxypropylidene)-19-nor-1α,25-$(OH)_2D_3$ (E-isomer) in an amount from about 0.01μg to about 100μg.

23. (Original) The pharmaceutical composition of claim 17 containing 2-(3'-hydroxypropylidene)-19-nor-1α,25-$(OH)_2D_3$ (E-isomer) in an amount from about 0.1μg to about 50μg.

24. (Original) The pharmaceutical composition of claim 17 containing 2-(3'-hydroxypropylidene)-19-nor-1α,25-$(OH)_2D_3$ (Z-isomer) in an amount from about 0.01μg to about 100μg.

25. (Original) The pharmaceutical composition of claim 17 containing 2-(3'-hydroxypropylidene)-19-nor-1α,25-$(OH)_2D_3$ (Z-isomer) in an amount from about 0.1μg to about 50μg.

26. (Original) The pharmaceutical composition of claim 17 containing 2-(3'-hydroxypropylidene)-19-nor-(20S)-1α,25-$(OH)_2D_3$ (E-isomer) in an amount from about 0.01μg to about 100μg.

27. (Original) The pharmaceutical composition of claim 17 containing 2-(3'-hydroxypropylidene)-19-nor-(20S)-1α,25-$(OH)_2D_3$ (E-isomer) in an amount from about 0.1μg to about 50μg.



28. (Original) The pharmaceutical composition of claim 17 containing 2-(3'-hydroxypropylidene)-19-nor-(20S)-1α,25-$(OH)_2D_3$ (Z-isomer) in an amount from about 0.01μg to about 100μg.

29. (Original) The pharmaceutical composition of claim 17 containing 2-(3'-hydroxypropylidene)-19-nor-(20S)-1α,25-$(OH)_2D_3$ (Z-isomer) in an amount from about 0.1μg to about 50μg.

85. (Withdrawn) A method of treating an autoimmune disease comprising administering to a patient with said disease an effective amount of a compound having the formula




where $Y_1$ and $Y_2$ which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, where X may be an alkyl, hydrogen, hydroxy-protecting group, hydroxyalkyl, alkoxyalkyl and aryloxyalkyl, and where the group R is represented by the structure:





where the stereochemical center at carbon 20 may have the R or S configuration, and where Z is selected from Y, -OY, -$CH_2$OY, -C≡CY and -CH=CHY, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, -$COR^5$ and a radical of the structure:



where m and n, independently, represent the integers from 0 to 5, where $R^1$ is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and $C_{1-5}$-alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of $R^2$, $R^3$, and $R^4$, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and $C_{1-5}$ alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where $R^1$ and $R^2$, taken together, represent an oxo group, or an alkylidene group, $=CR^2R^3$, or the group -$(CH_2)_p$-, where p is an integer from 2 to 5, and where $R^3$ and $R^4$, taken together, represent an oxo group, or the group -$(CH_2)_q$-, where q is an integer from 2 to 5, and where $R^5$ represents hydrogen, hydroxy, protected hydroxy, or $C_{1-5}$ alkyl and wherein any of the CH-groups at positions 20, 22, or 23 in the side chain may be replaced by a nitrogen atom, or where any of the groups -$CH(CH_3)$-, -$(CH_2)$m-, -$(CH_2)$n-, or –$(CR_1R_2)$- at positions 20, 22, and 23, respectively, may be replaced by an oxygen or sulfur atom.



86. (Withdrawn) The method of claim 85 where the disease is multiple sclerosis.

98. (Withdrawn) A method of treating an inflammatory bowel disease comprising administering to a patient with said disease an effective amount of a compound having the formula




where $Y_1$ and $Y_2$ which the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, where X may be an alkyl, hydrogen, hydroxy-protecting group, hydroxyalkyl, alkoxyalkyl and aryloxyalkyl, and where the group R is represented by the structure:






where the stereochemical center at carbon 20 may have the R or S configuration, and where Z is selected from Y, -OY, $-CH_2OY$, -C≡CY and -CH=CHY, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, $-COR^5$ and a radical of the structure:



where m and n, independently, represent the integers from 0 to 5, where $R^1$ is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and $C_{1-5}$-alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of $R^2$, $R^3$, and $R^4$, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and $C_{1-5}$ alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where $R^1$ and $R^2$, taken together, represent an oxo group, or an alkylidene group, $=CR^2R^3$, or the group $-(CH_2)_p-$, where p is an integer from 2 to 5, and where $R^3$ and $R^4$, taken together, represent an oxo group, or the group $-(CH_2)_q-$, where q is an integer from 2 to 5, and where $R^5$ represents hydrogen, hydroxy, protected hydroxy, or $C_{1-5}$ alkyl and wherein any of the CH-groups at positions 20, 22, or 23 in the side chain may be replaced by a nitrogen atom, or where any of the groups $-CH(CH_3)-$, $-(CH_2)m-$, $-(CH_2)n-$, or $-(CR_1R_2)-$ at positions 20, 22, and 23, respectively, may be replaced by an oxygen or sulfur atom.

99. (Withdrawn) The method of claim 98 wherein the disease is Crohn's disease.

100. (Withdrawn) The method of claim 98 wherein the disease is ulcerative colitis.



101. (Withdrawn) The method of claim 98 wherein the compound is administered orally.

102. (Withdrawn) The method of claim 98 wherein the compound is administered parenterally.

103. (Withdrawn) The method of claim 98 wherein the compound is administered transdermally.

104. (Withdrawn) The method of claim 98 wherein the compound is administered in a dosage of from about 0.01 μg/day to about 100 μg/day.